Regenxbio (NASDAQ:RGNX) Given “Buy” Rating at Evercore ISI
Evercore ISI restated their buy rating on shares of Regenxbio (NASDAQ:RGNX) in a report issued on Monday, AnalystRatings.com reports. Evercore ISI currently has a $65.00 price objective on the biotechnology company’s stock.
RGNX has been the topic of a number of other reports. Chardan Capital set a $150.00 price target on shares of Regenxbio and gave the stock a buy rating in a research report on Wednesday, September 4th. BidaskClub raised shares of Regenxbio from a sell rating to a hold rating in a research report on Thursday, October 3rd. Svb Leerink raised shares of Regenxbio from an underperform rating to a market perform rating and lowered their price target for the stock from $38.00 to $37.00 in a research report on Tuesday, August 20th. Leerink Swann raised shares of Regenxbio from an underperform rating to a market perform rating in a research report on Tuesday, August 20th. They noted that the move was a valuation call. Finally, Zacks Investment Research lowered shares of Regenxbio from a buy rating to a hold rating in a research report on Saturday, October 26th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $72.38.
NASDAQ:RGNX traded down $0.28 during mid-day trading on Monday, reaching $36.32. 356,500 shares of the company’s stock were exchanged, compared to its average volume of 559,129. Regenxbio has a one year low of $30.38 and a one year high of $65.62. The firm has a market capitalization of $1.42 billion, a PE ratio of 15.26 and a beta of 0.81. The business’s fifty day simple moving average is $37.56 and its two-hundred day simple moving average is $42.40. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.49 and a current ratio of 11.49.
In other Regenxbio news, SVP Patrick J. Christmas sold 5,486 shares of the firm’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $42.00, for a total value of $230,412.00. Following the transaction, the senior vice president now directly owns 8,058 shares of the company’s stock, valued at approximately $338,436. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Kenneth T. Mills sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $37.55, for a total transaction of $563,250.00. Following the completion of the transaction, the insider now directly owns 261,000 shares in the company, valued at $9,800,550. The disclosure for this sale can be found here. Over the last three months, insiders sold 30,486 shares of company stock worth $1,191,162. Insiders own 13.80% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the business. Berman Capital Advisors LLC increased its holdings in Regenxbio by 41.6% in the 2nd quarter. Berman Capital Advisors LLC now owns 1,133 shares of the biotechnology company’s stock valued at $58,000 after buying an additional 333 shares during the period. NEXT Financial Group Inc bought a new position in Regenxbio in the 2nd quarter valued at about $69,000. Royal Bank of Canada increased its holdings in Regenxbio by 36.2% in the 2nd quarter. Royal Bank of Canada now owns 3,910 shares of the biotechnology company’s stock valued at $201,000 after buying an additional 1,040 shares during the period. Virginia Retirement Systems ET AL bought a new position in Regenxbio in the 2nd quarter valued at about $216,000. Finally, Ellington Management Group LLC bought a new position in Regenxbio in the 2nd quarter valued at about $216,000. 79.54% of the stock is currently owned by hedge funds and other institutional investors.
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Further Reading: What is operating income?
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.